December 10, 2022Affinity, analysis, analytics, bio, business, Business Analysis, cannabinoid, cannabis, Christina Diarcangelo, clinical, diabetic, drug, Federal, government, growing, head, industry, lab, laboratories, laboratory, labs, law, legal, legalization, legalize, legislation, license, marijuana, medical, medicine, nerve, pain, Partners, pharma, pharmaceutical, product, Product Development, Quality, regulation, regulatory, safety, state, studies, Study, test, Testing, therapeutics, to, trial, Zelira First Pharma vs Cannabis Clinical Trial Moves Forward Affinity Bio Partners on Working with Zelira Therapeutics to Complete Enrolment for Diabetic Nerve Pain Drug Trial It’s an exciting time in […]